logo True scholar network
Back to Top
Visit Website Disclaimer

Cancer Letters (CL)

Publisher :

Elsevier

Scopus Profile
Peer reviewed only
Scopus Profile
Open Access
  • Cancer Research
  • Molecular Biology
  • Oncology

    • +2

e-ISSN :

1872-7980

Issue Frequency :

Continuously

Impact Factor :

16.7

p-ISSN :

0304-3835

Est. Year :

1975

Mobile :

204853911

Country :

Netherlands The

Language :

English

APC :

YES

Impact Factor Assignee :

Google Scholar

Email :

Min-Li@ouhsc.edu

Journal Descriptions

An international journal providing a forum for original and pertinent contributions in cancer research Cancer Letters is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and translational oncology. Additionally, Special Issues highlight topical areas in cancer research. Basic areas of interest to a broad readership of Cancer Letters include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal places emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine, including metronomic chemotherapy. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.


Cancer Letters (CL) is :

International, Peer-Reviewed, Open Access, Refereed, Cancer Research, Molecular Biology, Oncology, Medicine, Biochemistry , Online or Print, Continuously Journal

UGC Approved, ISSN Approved: P-ISSN - 0304-3835, E-ISSN - 1872-7980, Established in - 1975, Impact Factor - 16.7

Not Provide Crossref DOI

Indexed in Scopus, PubMed

Not indexed in WoS, DOAJ, UGC CARE

Indexing

Scopus Profile
Scopus
Scopus Profile
PubMed
Scopus Profile
Elsevier

+7 More

Publications of CL

Research Article
  • dott image James Turkson
  • dott image May, 2022

Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo

Signal transducer and activator of transcription (Stat)3 is a valid anticancer therapeutic target. We have discovered a highly potent chemotype that amplifies the Stat3-inhibitory activity o...

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile